1. Inhibition of ATP-Induced Glutamate Release by MRS2179 in Cultured Dorsal Spinal Cord Astrocytes
- Author
-
Huai-Zhen Ruan, Wen-Juan He, Xiao-Hong Liu, Jin-Hai Zhang, Xi-Gui Wu, Jun-Wei Zeng, and Lu Du
- Subjects
Time Factors ,Glutamic Acid ,Rats, Sprague-Dawley ,Receptors, Purinergic P2Y1 ,Adenosine Triphosphate ,Mediator ,Purinergic P2 Receptor Antagonists ,medicine ,Animals ,heterocyclic compounds ,Receptor ,Cells, Cultured ,Chromatography, High Pressure Liquid ,Pharmacology ,Calcium metabolism ,Microscopy, Confocal ,Dose-Response Relationship, Drug ,Receptors, Purinergic P2 ,Chemistry ,musculoskeletal, neural, and ocular physiology ,Purinergic receptor ,Glutamate receptor ,General Medicine ,Spinal cord ,Rats ,Cell biology ,Adenosine Diphosphate ,Posterior Horn Cells ,medicine.anatomical_structure ,Astrocytes ,Excitatory postsynaptic potential ,Calcium ,Neuroscience ,Astrocyte - Abstract
It was reported that ATP, an excitatory chemical mediator, exerts its effects by activation of the P2X (ligand-gated cationic channels) and P2Y (G protein-coupled receptors) purinoceptors in the nervous system. In the present work, we used confocal laser scanning microscopy and high-performance liquid chromatography to assess the role of the P2Y1 receptor in ATP-evoked Ca2+ mobilization and glutamate release from cultured dorsal spinal cord astrocytes. ATP (0.01–100 µmol/l) produces a dose-dependent rise in the Ca2+ relative fluorescence intensity in cultured astrocytes. N6methyl-2′-deoxyadenosine-3′,5′-bisphosphate (MRS2179, 0.01–100 µmol/l), a P2Y1-specific antagonist, could dose-dependently inhibit ATP-evoked Ca2+ mobilization. In addition, 100 µmol/l ATP caused glutamate efflux from cultured dorsal spinal cord astrocytes in a time-dependent manner. 100 µmol/l MRS2179 significantly inhibited the glutamate efflux induced by ATP, which suggests that P2Y1 receptor activation is responsible for the ATP-induced glutamate efflux from astrocytes. Taken together, our results demonstrate that P2Y1 receptor plays an important role in modulating the function of astrocytes, which raises the possibility that MRS2179, a potent P2Y1-specific antagonist, may become a potential drug in treating many chronic neurological diseases characterized by astrocytic activation in the nervous system.
- Published
- 2008